AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8463453 — intervention group
Group type: COMPARATOR
Intervention: Single doses of cocaine (30 mg intravenously) and morphine (10 mg intravenously)
Number of subjects: 20
Study 8463453 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily maintenance on buprenorphine
Number of subjects: 20
Study 3710059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid (4.3 g/100 ml)
Number of subjects: 13
Study 3710059 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 13
Study 30907272 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective open surgical repair
Number of subjects: 19489
Study 30907272 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective endovascular aortic repair
Number of subjects: 19489
Study 30907272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured open surgical repair
Number of subjects: 19489
Study 30907272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured endovascular aortic repair
Number of subjects: 19489
Study 30907272 — intervention group
Group type: COMPARATOR
Intervention: DREAM and EVAR-1 trials impact on elective open surgical repair
Number of subjects: 19489
Study 29971397 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 19009
Study 29971397 — intervention group
Group type: COMPARATOR
Intervention: Liquid-based cytology (LBC) testing
Number of subjects: 19009
Study 27601892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehab (telephone health-mentoring targeting home-based walking)
Number of subjects: 40
Study 27601892 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waiting time before PR)
Number of subjects: 40
Study 27601892 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (part of PR)
Number of subjects: 40
Study 27601892 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not attending supervised exercise
Number of subjects: 40
Study 24573909 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic containers for medication
Number of subjects: 226
Study 24573909 — intervention group
Group type: COMPARATOR
Intervention: Standard packaging for medication
Number of subjects: 226
Study 21756152 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser therapy (FLT) combined with intermittent daily topical bleaching (5 treatments)
Number of subjects: 14
Study 21756152 — intervention group
Group type: COMPARATOR
Intervention: Intermittent regimen of topical bleaching alone
Number of subjects: 14
Study 21302191 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoplasty
Number of subjects: 126
Study 21302191 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc Dekompressor
Number of subjects: 126
Study 17373163 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-msec alexandrite laser treatment with fluences between 8 and 32 J/cm2
Number of subjects: 31
Study 17373163 — intervention group
Group type: COMPARATOR
Intervention: Laser only treated area
Number of subjects: 31
Study 17373163 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser/TCS treated area
Number of subjects: 31
Study 17373163 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (TCS) cream (betamethasone dipropionate)
Number of subjects: 31
Study 17373163 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-msec alexandrite laser treatment
Number of subjects: 31
Study 16115312 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-based, community oriented teaching model in family medicine (experimental model)
Number of subjects: 84
Study 16115312 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching curriculum (control group)
Number of subjects: 84
Study 12381083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of vitamin C
Number of subjects: 39
Study 12381083 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 39
Study 12381083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of KD (no gamma globulin treatment)
Number of subjects: 39
Study 12381083 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 39
Study 12381083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 39
Study 11067699 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based educational intervention for urinary incontinence (specific details on dosage and duration not available)
Number of subjects: 0
Study 11067699 — intervention group
Group type: COMPARATOR
Intervention: Wait control condition
Number of subjects: 0
Study 8986207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol dose (0.48 g/kg/LBM)
Number of subjects: 24
Study 8986207 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol dose (0.72 g/kg/LBM)
Number of subjects: 24
Study 8986207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1336131 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH/DHE (low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg, once a day)
Number of subjects: 179
Study 1336131 — intervention group
Group type: COMPARATOR
Intervention: HDHE (sodium heparin 5,000 U plus dihydroergotamine 0.5 mg, twice a day)
Number of subjects: 179
Study 6725660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralens and ultraviolet A (PUVA)
Number of subjects: 42
Study 6725660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B (UVB)
Number of subjects: 42
Study 6725660 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PUVA and UVB
Number of subjects: 42
Study 6725660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative doses of PUVA and UVB
Number of subjects: 42
Study 31206066 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician facecard
Number of subjects: 149
Study 31206066 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study 31206066 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteboard with attending name
Number of subjects: 149
Study 31206066 — intervention group
Group type: EXPERIMENTAL
Intervention: Facecard and whiteboard
Number of subjects: 149
Study 31206066 — intervention group
Group type: EXPERIMENTAL
Intervention: Facecard (hospitalists' perspective)
Number of subjects: 149
Study 30335875 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary thyroid cancer terminology
Number of subjects: 550
Study 30335875 — intervention group
Group type: COMPARATOR
Intervention: Papillary lesion terminology
Number of subjects: 550
Study 30335875 — intervention group
Group type: COMPARATOR
Intervention: Abnormal cells terminology
Number of subjects: 550
Study 27075606 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D virtual image guidance (3DV)
Number of subjects: 37
Study 27075606 — intervention group
Group type: COMPARATOR
Intervention: Conventional cross-sectional computed tomography (CT) image guidance
Number of subjects: 37
Study 27075606 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume surgeons
Number of subjects: 37
Study 25183657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol therapy (50,000 IU twice weekly)
Number of subjects: 15
Study 25183657 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal kidney function), n=15
Number of subjects: 15
Study 23044477 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal scaphoid excision followed by DIC ligament excision
Number of subjects: 10
Study 23044477 — intervention group
Group type: COMPARATOR
Intervention: DIC ligament excision alone
Number of subjects: 10
Study 23044477 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal scaphoid excision after DIC ligament excision
Number of subjects: 10
Study 23044477 — intervention group
Group type: COMPARATOR
Intervention: Control (original location before intervention)
Number of subjects: 10
Study 19778914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal HC gp-39 (30, 150, 300, or 600 microg, once a week)
Number of subjects: 0
Study 19778914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18364685 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits for dietary advice
Number of subjects: 376
Study 18364685 — intervention group
Group type: COMPARATOR
Intervention: Routine assistance from paediatricians (Control)
Number of subjects: 376
Study 15932704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1004
Study 15932704 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1004
Study 12414853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral DHEA (50 mg/d)
Number of subjects: 61
Study 12414853 — intervention group
Group type: COMPARATOR
Intervention: Conventional hormonal replacement therapy (HRT) (20 micro g ethinyl estradiol/0.1 mg levonorgestrel)
Number of subjects: 61
Study 10334133 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP + TBNA
Number of subjects: 55
Study 10334133 — intervention group
Group type: EXPERIMENTAL
Intervention: TBNA alone
Number of subjects: 55
Study 10334133 — intervention group
Group type: COMPARATOR
Intervention: CDP
Number of subjects: 55
Study 8565604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 percent metronidazole gel applied twice daily to the right side of the face
Number of subjects: 6
Study 8565604 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent permethrin cream applied daily to the left side of the face
Number of subjects: 6
Study 8565604 — intervention group
Group type: COMPARATOR
Intervention: 0.75 percent metronidazole gel
Number of subjects: 6
Study 8565604 — intervention group
Group type: COMPARATOR
Intervention: 5 percent permethrin cream
Number of subjects: 6
Study 31994767 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain attention training
Number of subjects: 78
Study 31994767 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 78
Study 30318741 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-degree selective laser trabeculoplasty (SLT)
Number of subjects: 0
Study 30318741 — intervention group
Group type: COMPARATOR
Intervention: 360-degree selective laser trabeculoplasty (SLT)
Number of subjects: 0
Study 28161303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (GLP-1 group)
Number of subjects: 36
Study 28161303 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (Control group)
Number of subjects: 36
Study 25683227 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE (novel electronic medical record dashboard)
Number of subjects: 80
Study 25683227 — intervention group
Group type: COMPARATOR
Intervention: Existing EMR (control)
Number of subjects: 80
Study 23392314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 3-snip punctoplasty with self-retaining bicanaliculus stents (Group B)
Number of subjects: 32
Study 23392314 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-snip punctoplasty (Group A)
Number of subjects: 32
Study 21482950 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.5 mg/day)
Number of subjects: 120
Study 21482950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17289660 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management course (n = 78)
Number of subjects: 180
Study 17289660 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 180
Study 15644830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Budesonide Inhalation Suspension (BIS)
Number of subjects: 141
Study 15644830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg Budesonide Inhalation Suspension (BIS)
Number of subjects: 141
Study 15644830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 12897288 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician aware of rapid influenza test result
Number of subjects: 418
Study 12897288 — intervention group
Group type: COMPARATOR
Intervention: Physician unaware of rapid influenza test result
Number of subjects: 418
Study 11109684 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 0
Study 11109684 — intervention group
Group type: EXPERIMENTAL
Intervention: High intervention
Number of subjects: 0
Study 11109684 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 8853758 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 209
Study 8853758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 1513963 — intervention group
Group type: EXPERIMENTAL
Intervention: School-and-home condition (n = 45)
Number of subjects: 132
Study 1513963 — intervention group
Group type: EXPERIMENTAL
Intervention: School-only condition (n = 43)
Number of subjects: 132
Study 1513963 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 44)
Number of subjects: 132
Study 6482417 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical transformations using synthesized /Cej/‐type utterances with different F2 and F3 onset frequencies
Number of subjects: 8
Study 6482417 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictions of percent /r/ responses derived from regression analyses based on mel transformations and Bark transformations
Number of subjects: 8
Study 6482417 — intervention group
Group type: EXPERIMENTAL
Intervention: Category boundaries estimation
Number of subjects: 8
Study 30755464 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen-tot services plus 5 interactive parenting and life skills modules delivered by a nurse and social worker over the infant's first 15 months
Number of subjects: 140
Study 30755464 — intervention group
Group type: COMPARATOR
Intervention: Teen-tot services alone
Number of subjects: 140
Study 29967649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (8 weeks, twice weekly)
Number of subjects: 27
Study 29967649 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 27
Study 27659507 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of sputum using Xpert MTB/RIF assay and urine using Determine TB-LAM and Xpert after urine concentration by centrifugation
Number of subjects: 1300
Study 27659507 — intervention group
Group type: COMPARATOR
Intervention: Testing of sputum using Xpert MTB/RIF assay (standard of care)
Number of subjects: 1300
Study 24175912 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLC) Program including diet (overweight: 1700 kcal/day, obese: 1800 kcal/day) and mild physical activity (30 min/day, 3 times/week)
Number of subjects: 61
Study 24175912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 24175912 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLC) Program
Number of subjects: 61
Study 21889306 — intervention group
Group type: EXPERIMENTAL
Intervention: DASS‐21 depression subscale
Number of subjects: 154
Study 21889306 — intervention group
Group type: EXPERIMENTAL
Intervention: DASS‐21 anxiety subscale
Number of subjects: 154
Study 21889306 — intervention group
Group type: EXPERIMENTAL
Intervention: DASS‐21 stress subscale
Number of subjects: 154
Study 21889306 — intervention group
Group type: EXPERIMENTAL
Intervention: DASS‐21 aggregate score of 'negative affect'
Number of subjects: 154
Study 20353105 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with active-blood and dissolve-stasis herbs and rehabilitation training (Group A)
Number of subjects: 320
Study 20353105 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with rehabilitation training (Group B)
Number of subjects: 320
Study 20353105 — intervention group
Group type: COMPARATOR
Intervention: Herbs combined with rehabilitation training (Group C)
Number of subjects: 320
Study 20353105 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training alone (Group D)
Number of subjects: 320
Study 18181732 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (specific strains not detailed)
Number of subjects: 0
Study 18181732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG and Saccharomyces boulardii
Number of subjects: 0
Study 15960409 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 60
Study 15960409 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 14557456 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured with the euglycemic, hyperinsulinemic clamp
Number of subjects: 84
Study 14557456 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin secretion measured as the acute response to iv arginine (5 g)
Number of subjects: 84
Study 14557456 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IMT (0.81 ± 0.14 mm) and progression in IMT over 5 years
Number of subjects: 84
Study 14557456 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal IMT (1.42 ± 0.42 mm) at baseline
Number of subjects: 84
Study 10851578 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistulectomy
Number of subjects: 40
Study 10851578 — intervention group
Group type: COMPARATOR
Intervention: Fistulotomy
Number of subjects: 40
Study 8609098 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized asthma self-management
Number of subjects: 34
Study 8609098 — intervention group
Group type: EXPERIMENTAL
Intervention: Group asthma self-management
Number of subjects: 34
Study 8609098 — intervention group
Group type: COMPARATOR
Intervention: Control (no self-management training)
Number of subjects: 34
Study 1953004 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release salbutamol (CRS)
Number of subjects: 16
Study 1953004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7458885 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline or imipramine
Number of subjects: 92
Study 7458885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 31781100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-PS vaccine
Number of subjects: 0
Study 31781100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi-TT vaccine
Number of subjects: 0
Study 29722285 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.5 µg/kg/minute (Group R 0.5)
Number of subjects: 75
Study 29722285 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.0 µg/kg/minute (Group R 1.0)
Number of subjects: 75
Study 29722285 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Group S)
Number of subjects: 75
Study 27454267 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous bipolar RF neurotomy on S2 and S3 nerves
Number of subjects: 10
Study 27454267 — intervention group
Group type: COMPARATOR
Intervention: Optimized conventional treatment
Number of subjects: 10
Study 27454267 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic study (UDS) parameters
Number of subjects: 10
Study 23828194 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera‐ and software‐based device (FACE)
Number of subjects: 100
Study 23828194 — intervention group
Group type: COMPARATOR
Intervention: Dye‐staining method
Number of subjects: 100
Study 23828194 — intervention group
Group type: COMPARATOR
Intervention: Visual‐tactile inspection
Number of subjects: 100
Study 22801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 μg kg(‐1)
Number of subjects: 96
Study 22801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 μg kg(‐1)
Number of subjects: 96
Study 22801581 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3 μg kg(‐1)
Number of subjects: 96
Study 20934602 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexercise supplement (Game Time; containing caffeine, creatine, and amino acids)
Number of subjects: 10
Study 20934602 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexercise supplement (Game Time)
Number of subjects: 10
Study 20934602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 19017831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 3535
Study 19017831 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 3535
Study 19017831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-released nifedipine
Number of subjects: 3535
Study 19017831 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3535
Study 16539632 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 20
Study 16539632 — intervention group
Group type: COMPARATOR
Intervention: No Thymoglobulin
Number of subjects: 20
Study 12721186 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day embryo culture
Number of subjects: 226
Study 12721186 — intervention group
Group type: COMPARATOR
Intervention: 2-day embryo culture
Number of subjects: 226
Study 12721186 — intervention group
Group type: COMPARATOR
Intervention: Arrested embryos transfer
Number of subjects: 226
Study 12721186 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst transfer on day 5
Number of subjects: 226
Study 11232384 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Clinical Demonstration Methodology (SCDM)
Number of subjects: 0
Study 8549030 — intervention group
Group type: EXPERIMENTAL
Intervention: Netivudine 400 mg
Number of subjects: 24
Study 8549030 — intervention group
Group type: EXPERIMENTAL
Intervention: Netivudine 800 mg
Number of subjects: 24
Study 8549030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1677894 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 12
Study 1677894 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 12
Study 1677894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6838671 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (specific popular diet free of additives, preservatives, fruit, red meat, herbs, and dairy products)
Number of subjects: 26
Study 6838671 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 26
Study 31452928 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg + methotrexate
Number of subjects: 1197
Study 31452928 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg + methotrexate
Number of subjects: 1197
Study 31452928 — intervention group
Group type: COMPARATOR
Intervention: placebo + methotrexate
Number of subjects: 1197